Antibodies
13 January 2025
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma13 January 2025
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform13 January 2025
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs11 January 2025
Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases11 January 2025
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States11 January 2025
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease11 January 2025
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers10 January 2025
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate9 January 2025
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis9 January 2025
Leyden Labs Raises $70M to Advance its Intranasal Antibody Programs to Protect against Influenza and other VirusesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports